Isis Pharmaceuticals (ISIS +8.4%) enjoys a strong session after BMO reiterates its Outperform...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS +8.4%) enjoys a strong session after BMO reiterates its Outperform rating and raises its price target to $31 from $22 citing a meeting with the company's SVP of Clinical Development regarding ISIS' antisense oligonucleotide pipeline. Separately, ISIS renews its lab testing agreement with Ontario-based CML HealthCare.